AUS
NZ
UK
CA
USA
IND
Celadon Pharmaceuticals PLC (LSE:CEL) announced on Monday that it is still awaiting essential cash inflows, though its operations remain aligned with internal expectations.
Market Reaction and Share Performance
The company's shares dropped by 47% to 28.00 pence each in London on Monday morning. Over the past year, the stock has declined by 81%.
Financial Challenges and Funding Delays
Celadon, based in London, is facing financial strain due to a delay in receiving funds from its third equity admission and a £1 million drawdown from a committed credit facility. These delays have compounded the company's cash position difficulties.
Operational Progress and Future Prospects
Despite the financial challenges, Celadon reports continued operational progress. This includes the supply of cannabis Active Pharmaceutical Ingredients (APIs) to UK specials manufacturers, which are then distributed to private pain clinics in the UK. CEO James Short noted positive discussions with potential lenders about securing substantial new long-term debt facilities. Both investors and lenders have reaffirmed their commitment and support for the company, despite the funding delays.
Financial Management and Facility Expansion
Celadon is actively managing its financial situation while working on fulfilling initial UK customer orders from its Midlands facility. Due to limited capacity at this facility, the company is exploring alternative methods for supplying pharmaceutical-grade cannabis to its European clients, as previously announced on November 16, 2023.
